A phase II and pharmacokinetic study with oral piritrexim for metastatic breast cancer.

Piritrexim is a lipid-soluble antifolate which, like methotrexate, has a potent capacity to inhibit dihydrofolate reductase. We performed a multicentre phase II study with piritrexim in patients with locally advanced or metastatic breast cancer. Twenty-four patients of which sixteen had received pri...

Descripción completa

Detalles Bibliográficos
Autores principales: de Vries, E. G., Gietema, J. A., Workman, P., Scott, J. E., Crawshaw, A., Dobbs, H. J., Dennis, I., Mulder, N. H., Sleijfer, D. T., Willemse, P. H.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1993
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968400/
https://www.ncbi.nlm.nih.gov/pubmed/8353055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968400/
https://www.ncbi.nlm.nih.gov/pubmed/8353055

Ejemplares similares